Stay updated with breaking news from Refractive Surgery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
WASHINGTON — Patients who underwent Dextenza implantation had improvements in itching due to allergic conjunctivitis through 30 days, according to a study.
HEIDELBERG, Germany, and CAMBRIDGE, Mass., April 26, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical...
Alcon (NYSE:ALC) announced data from a clinical study supporting the use of its SmartCataract solutions for cataract surgery.
/PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Novaliq GmbH, a...